YuanBio Venture Capital — 2021 Investments
1 investments dated 2021 · listed companies and verified rows first · show all
Alebundalebund.cominSep 2021 · $54.5M
An innovative biopharmaceutical company focused on developing therapies for chronic kidney disease across multiple clinical stages, with a pipeline of eight products covering conditions such as hyperphosphatemia, renal anemia, IgA nephropathy, and diabetic kidney disease.
BiotechDigital HealthHealthtechMedical DevicesShanghai, CN
Co-investorsLAVLilly Asia VenturesQuan Capital3E Bioventures Capital3H Health InvestmentSherpa Healthcare Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.